Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birtamimab Open-label Extension in AL Amyloidosis
NCT02613182Phase 2Terminated
- Sponsor
- Prothena Corporation
- Start
- Feb 2016
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of birtamimab in amyloid light chain amyloidosis, sponsored by Prothena Corporation. Started Feb 2016; status: terminated.
02
Drugs
birtamimab
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT02613182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613182.